"Results Of Novel In Situ Vaccine: Vaccine Is Created Directly At The Tumor Site, Minor Side Effects Like Fever Or Flu Like Symptoms"
Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at Mount Sinai discusses vaccines. “By vaccine, we mean a therapeutic vaccine, a vaccine to treat a problem that’s already there, not a preventative vaccine. He added, “This therapeutic vaccine is designed to treat lymphoma, and it’s exciting for us because now we have a new ongoing trial combining the vaccine with a new immunotherapy.”
— Joshua Brody, MD, Director, Lymphoma Immunotherapy Program, The Tisch Cancer Institute, Assistant Professor, Medicine, Hematology, Medical Oncology, Icahn School of Medicine at Mount Sinai
Mount Sinai Researchers Make Immunotherapy Work for Treatment-Resistant Lymphoma
Aug 02, 2019 View All Press ReleasesMount Sinai Researchers Develop Treatment That Turns Tumors Into Cancer Vaccine Factories
Apr 08, 2019 View All Press Releases